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Interferon- is required for lupus nephritis in mice treated [2] and can have a direct pathogenic role in glomerulo-
with the hydrocarbon oil pristane. nephritis [3, 4]. Nephritis and autoantibodies characteris-
Background. Although the precise mechanisms leading to tic of systemic lupus erythematosus (SLE) also occurlupus nephritis remain obscure, both TH1 and TH2 cytokines
spontaneously in certain strains of mice, such as NZB/Whave been implicated. The present study examined the roles of
(F1) and MRL/lpr [4]. Murine lupus models facilitateinterleukin (IL)-4 and interferon- (IFN-) in a novel inducible
form of lupus that develops in non-autoimmune mice treated studies of the relationship between autoantibody forma-
with the hydrocarbon oil pristane. tion and end organ damage [4–6]. Like SLE, murine
Methods. BALB/c IL-4 or IFN- deficient mice (IL-4 /, lupus has a strong genetic component [7]. However,IFN /) and wild type controls (/) received either pris-
there are differences between murine and human lupus.tane or phosphate-buffered saline (PBS) IP. Serial sera were
Although glomerular immune complex deposits can beanalyzed for anti-DNA/chromatin, anti-RNP/Sm, and total
immunoglobulin levels. Proteinuria was measured and kid- found in virtually every lupus patient [8], only 30 to
neys were examined by direct immunofluorescence and light 60% develop overt nephritis [9]. In contrast, nearly all
microscopy.
NZB/W (F1) and MRL/lpr mice have advanced nephritisResults. Renal disease did not develop in pristane-treated
by six to eight months of age [10]. Moreover, the spec-IFN- / mice, as assessed by the absence of capillary im-
mune deposits, glomerular pathology and proteinuria whereas trum of autoantibodies produced by NZB/W mice and
IL-4 / mice developed renal disease similar to / mice. to a lesser degree MRL/lpr differs substantially from that
Production of IgG anti-single stranded DNA and anti-chroma- of SLE.
tin antibodies was abrogated in IFN- / mice. In contrast,
Lupus also can be induced using the hydrocarbon oilthese autoantibodies were produced at similar or higher fre-
pristane in non-autoimmune prone strains of mice, in-quencies and levels by IL-4 / versus wild-type mice. The
frequency of anti-nRNP/Sm was markedly reduced in IFN- cluding BALB/c, SJL, C57BL/6 (B6), and others [11, 12].
/ mice. IL-4 deficiency had little effect on the production The syndrome induced by pristane shares many of the
of anti-DNA/chromatin and anti-nRNP/Sm. characteristics of human lupus including both clinicalConclusions. IFN- is essential for the induction of nephri-
features (arthritis, serositis, glomerular hypercellularity,tis and anti-DNA/chromatin following pristane exposure in
glomerular IC deposition, proteinuria) and the autoanti-BALB/c mice, suggesting that genetic or environmental fac-
tors influencing TH1-TH2 balance could be an important deter- body profile (anti-dsDNA, -nRNP/Sm, -Su, -chromatin,
minant of renal disease in lupus. -histone) [13]. Following pristane treatment, 30 to 40%
of BALB/c mice develop glomerular immunoglobulin
and complement deposition, marked mesangial hyper-
Lupus nephritis is the prototype human immune com- cellularity and proteinuria closely resembling lupus ne-
plex disease [1]. It is associated with disease-specific phritis [14]. This frequency of overt nephritis is akin to
autoantibodies, such as anti-double-stranded (ds) DNA human SLE. Although the precise mechanisms involved
and anti-Sm, which are enriched in glomerular eluates in the development of lupus-like disease in this model
remain to be defined the profound imbalance in cytokine
homeostasis induced by pristane [15] may be integral toKey words: glomerulonephritis, antinuclear antibodies, pristane, im-
mune complex disease, systemic lupus erythematosus. the pathogenesis of pristane-induced lupus. Indeed, there
is evidence that alteration in cytokine balance alone isReceived for publication April 25, 2001
sufficient to induce autoimmunity [16].and in revised form June 14, 2001
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Table 1. Renal lesions in BALB/cJ mice 7.5 months after treatment
% of mice positive
Strain Rx N IgG1a IgG2aa IgG2ba IgG3a IgMa C3a Capb LMc Prot.d
/ Prist. 15 40 46 20 33 26 53 13 33 33
/ PBS 8 0 0 0 0 0 0 0 0 0
IL-4 / Prist. 18 39f 73f 11 56f 73f 73f 28 56f 11
IL-4 / PBS 6 0 0 0 0 0 0 0 0 0
IFN- / Prist. 21 0e 10e 5 0e 24 24 0 5 0e
IFN- / PBS 5 0 0 0 0 0 0 0 0 0
Abbreviations are: IL-4, interleukin-4; IFN-, interferon-gamma; Rx, treatment; Prist., pristane; PBS, phosphate-buffered saline; IgG, immunoglobulin G.
a Positive renal mesangial and/or capillary pattern immunofluorescence on frozen sections for IgG1, IgG2a, IgG2b, IgG3, IgM, or C3
b Presence of staining in a capillary pattern
c Presence of light microscopic (LM) changes by hematoxylin and eosin staining (H&E)
d Proteinuria (3 or 300 mg/dL) 7.5 months after pristane treatment
e P  0.05 / vs. IFN- / pristane treated mice (Fisher exact test)
f P  0.05 IFN- / vs. IL-4 / pristane treated mice (Fisher exact test)
[19–22]. But the importance of TH1 versus TH2 cytokines For immunofluorescence, tissue was embedded in OCT
Compound (Miles) and 4 m unfixed frozen sectionsin lupus is controversial, perhaps reflecting heterogeneity
were stained with 1:20 goat anti-mouse IgG1, -2a, -2b,of the disease. A more complete picture of lupus can be
or -3, or IgM (Southern Biotechnology, Birmingham,achieved by defining how cytokines shape the phenotype
AL, USA) or with rabbit anti-mouse C3 (Cappel Labora-of lupus in several models. The goal of this study was to
tories, Durham, NC, USA). Glomerular staining wasevaluate the effects of TH1 versus TH2 cytokines in pris-
graded by intensity (0  no staining, 4  maximumtane-induced lupus. We show that the proinflammatory
intensity staining) and pattern (predominantly mesangialcytokine IFN- plays a key role in the development of
vs. capillary plus mesangial). Background was definedboth autoantibodies and nephritis in pristane-treated mice.
as the strongest staining observed in PBS treated control
mice (IFN- /, IL-4 / and /) and only staining
METHODS above background was considered as positive. The Fisher
exact test with Bonferoni’s correction for multiple com-Mice
parisons was used for statistical analysis.Female BALB/cJ IFN-–deficient (IFN/) or IL-4–
deficient (IL-4 /) mice and age/sex matched controls Immunoprecipitation
(/) (Jackson Laboratory, Bar Harbor, ME, USA),
Immunoprecipitation of [35S] methionine labeled cellage 10 to 12 weeks were housed in specific pathogen
extract from K562 (human erythroleukemia) cells wasfree conditions. They received 0.5 mL of pristane (2, 6,
performed as described [19].10, 14-tetramethylpentadecane; Sigma Chemical Co., St.
Louis, MO, USA) or an equal volume of PBS IP [14]. Anti-nRNP/Sm ELISA
Serum samples were collected from the tail vein before
Anti-nRNP/Sm antigen capture ELISA was performed
treatment, two weeks later, and then at one-month inter- as described [24]. Briefly, the wells of microtiter plates
vals. At 7.5 months, kidneys were processed for light were coated with monospecific purified human IgG anti-
and immunofluorescence microscopy. Proteinuria was nRNP/Sm. Wells were washed and K562 cell lysate was
measured with Albustix (Miles Laboratories, Elkhart, added to half of the wells and buffer alone to the other
IN, USA). Proteinuria3 (300 mg/dL) was considered half. After washing, mouse sera diluted 1:500 were added
significantly elevated. to the wells. Alkaline phosphatase-conjugated goat anti-
mouse IgG ( chain-specific; Southern Biotechnology)Renal pathology
was used as second antibody. The plates were developed
Renal lesions were graded in a blinded manner [23]. with p-nitrophenyl phosphate substrate and OD was
For light microscopy (LM), tissue was fixed in 4% para- read at 405 nm. To correct for non-specific binding, OD
formaldehyde and 3 m paraffin sections were stained values obtained from the control wells (no antigen) were
with periodic acid Schiff (PAS) and hematoxylin and subtracted from the values from antigen-coated wells.
eosin (H&E). Sections were graded as follows: 1  Using Y2 (anti-Sm-B mAb) culture supernatant as a
mild focal mesangial hypercellularity alone; 2  mod- standard anti-nRNP/Sm activity (arbitrary units) for
erate mesangial hypercellularity; 3  complex endo- each sample was determined.
capillary hypercellularity sometimes with mild sclerosis
Anti-ssDNA and anti-chromatin ELISAor necrosis; 4 severe endocapillary proliferative glo-
merulonephritis with necrosis or crescent formation. Anti-ssDNA, and anti-chromatin autoantibody levels
were determined by enzyme-linked immunosorbent assayScores 1 were positive.
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Fig. 1. Renal disease. (A–D) Light microscopy. Renal tissue from mice 7.5 months after treatment was fixed in 4% paraformaldehyde and 3 m
paraffin sections were stained with PAS. (A) PBS-treated / with normal glomeruli. (B) Pristane-treated / with extensive endocapillary
hypercellularity, thickening of the capillary walls, obliteration of capillary lumens and segmental sclerosis (note glomerular enlargement). (C)
Pristane-treated IL-4/with well defined mesangial expansion. (D) pristane-treated IFN-/with a normal glomerulus. (E–H ) Immunofluores-
cence. Four micrometer unfixed frozen sections 7.5 months after treatment were stained with 1:20 goat anti-mouse IgG2a. (E) PBS-treated /
with no significant staining for IgG2a. (F) Pristane-treated / with marked capillary and mesangial IgG2a. (G) Pristane-treated IL-4 / with
capillary and granular mesangial IgG2a. (H) Pristane-treated IFN- / with granular mesangial IgG2a.
(ELISA) using sera diluted 1:500 [19]. Secondary anti- RESULTS
bodies were alkaline phosphatase-conjugated goat anti- T cells are central to the pathogenesis of lupus auto-
mouse IgG (1:1000 dilution; Southern Biotechnology). antibodies in pristane-treated mice [23]. To further de-
For the anti-chromatin ELISA, a high titer positive fine their role, we asked whether cytokines produced by
MRL/lpr serum served as a standard and the cutoff was helper T cell subsets are required for the induction of
the mean  3 SD of 11 PBS-treated wild-type control glomerulonephritis. For this purpose lupus-like disease
mice for each time point. was induced in IL-4– or IFN-–deficient BALB/c mice.
No spontaneous nephritis or lupus-related autoantibodyTotal IgG levels
production have been reported in either of these strains
Total levels of each isotype were determined by ELISA [25, 26].
as described [19]. Microtiter plate wells were coated with
goat anti-mouse /	 light chain antibodies (Southern Pristane-induced lupus nephritis is IFN- dependent
Biotechnology). Sera were diluted 1:200,000 and added
The induction of renal disease was examined in miceto the wells. After washing, the wells were incubated with
that were alive at 7.5 months after pristane treatment.alkaline phosphatase-labeled goat anti-mouse antibodies
As in SLE patients and in marked contrast to the nearlyspecific for IgG1 and 2a (1:1000 dilution, Southern Bio-
100% frequency of renal disease in NZB/W and MRL/technology), substrate was added, and OD determined
lpr mice [10], pristane induced proteinuria, immune com-at 405 nm as above. Isotype standards were used for
plex deposition, and histological changes in about one-standard curve fitting and Ig concentrations were calcu-
third of BALB/c / mice (Table 1 and Fig. 1 A, B,lated using Softmax software.
E, F). When compared with / controls and IL-4 /
Anti-dsDNA assay mice, pristane-treated IFN- / mice had a markedly
reduced frequency of immune deposits and capillaryThe Crithidia luciliae assay (The Binding Site, Bir-
involvement was absent (Table 1 and Fig. 1 D, H).mingham, UK) was used to analyze sera (1:20 dilution)
Only 1/21 pristane-treated IFN- / mice had mildfor anti-dsDNA antibodies [19]. Secondary antibody was
focal mesangial hypercellularity. The remainder had noFITC conjugated goat anti-mouse IgG (Southern Bio-
technology). LM changes (Fig. 1D). IgG2a (Fig. 1H) deposits in a
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predominantly mesangial pattern were found in only 2 association between nephritis and anti-chromatin in/
of 21 pristane-treated IFN- / mice. None developed and IL-4 / mice, but this did not achieve statistical
significant proteinuria (Table 1). Given their low levels significance. No other autoantibody specificities were as-
of total IgG2a (Fig. 4), the presence of moderate glomer- sociated with renal disease.
ular IgG2a deposits in 10% of IFN- /mice was Although not implicated in renal disease, anti-nRNP/
unexpected. Specificity of the labeled antibody for IgG2a Sm are highly characteristic of SLE [27]. Pristane in-
was verified using myeloma proteins (not shown). duced anti-nRNP/Sm in 78% of / mice (Table 2 and
Following pristane treatment,/ and IL-4/mice Fig. 2C, left). The frequencies in IL-4/ and/mice
had similar immune complex deposits, with the exception were comparable, but levels were generally lower in the
of IgM (Table 1 and Fig. 1 F, G). LM changes were most IL-4 / group (Fig. 2C, right). In contrast, the fre-
advanced in some of the pristane-treated / mice in quency of anti-nRNP/Sm in IFN- / mice was only
which diffuse proliferative glomerulonephritis with seg- 22% (5 of 22 mice, P  0.05 vs. / and IL-4 /
mental necrosis was seen (Fig. 1B). LM changes in pris- groups, Fisher exact test). Remarkably, the positive mice
tane-treated IL-4 / mice were somewhat milder with had anti-nRNP/Sm levels comparable to those in /
focal or widespread moderate mesangial hypercellularity controls (Fig. 2C, right), and they were readily detectable
(Fig. 1C). However, pathological findings were more
by immunoprecipitation (Fig. 3). Anti-nRNP/Sm anti-common than in/ controls. There was a trend toward
bodies also were readily detectable in IL-4 / miceless frequent proteinuria in pristane-treated IL-4/
(Fig. 3), suggesting that their avidity was high. Moreover,mice that may reflect a decrease in glomerular filtration
since the immunoprecipitates were absorbed onto pro-rate in this group. However, this trend was statistically
tein A-Sepharose beads, the strong signal suggested thatnot significant. Immune deposits and LM changes were
IgG2a and/or IgG2b anti-nRNP/Sm autoantibodies werenot seen in PBS-treated mice (Table 1, Fig. 1 A, E). In
produced in view of the poor binding of mouse IgG1contrast to MRL mice, tubulointerstitial changes were
and IgG3 to protein A. Unexpectedly, given the strongabsent in pristane-treated mice as well as PBS controls.
dependence of this isotype on IFN- [28] and relative
Autoantibody production is IFN- dependent lack of IgG2a in IFN- / mice [26], anti-nRNP/Sm
were predominantly IgG2a in IFN- / mice (notAnti-DNA autoantibodies are associated with lupus
shown). Anti-Su autoantibodies were greatly decreasednephritis in humans [4]. As shown in Figure 2A, some
pristane-treated / and IL-4 / mice had markedly in IFN- / versus / or IL-4 / mice, as well
elevated levels of IgG anti-ssDNA (ELISA) at 7.5 (Fig. 3 and Table 2). Spontaneous production of anti-
months. In contrast, IFN-/mice had very low levels, nRNP/Sm or Su was not observed in PBS-treated mice
suggesting that IgG anti-ssDNA antibodies are IFN- by either immunoprecipitation or ELISA (not shown).
dependent. More importantly, the frequency of IgG anti-
Pristane unexpectedly stimulates IgG2a production indsDNA was much lower in pristane-treated IFN- /
versus / mice, whereas the absence of IL-4 had little IFN- / mice
or no effect (Table 2). Thus, IFN-, but not IL-4, defi- Although IgG2a is strongly IFN- dependent [28], it
ciency markedly attenuated the production of autoanti- was the predominant isotype of anti-nRNP/Sm autoanti-
bodies implicated in the pathogenesis of lupus nephritis. bodies and was enriched in the glomerular immune de-
IgG anti-chromatin autoantibodies in pristane-induced posits of IFN- / mice. We therefore examined the
lupus are highly IL-6 dependent [19] and correlate closely effect of IFN- or IL-4 deficiency on total immunoglobu-
with nephritis (abstract; Richards, Arthritis Rheum 42:
lin levels. As expected, pristane treated / mice mark-S361, 1999). Pristane induced IgG anti-chromatin anti-
edly increased their IgG1 and IgG2a levels versus PBS-bodies at levels comparable to those in MRL/lpr mice
treated controls (Fig. 4). IgG2a showed the same patternin some of the/ and IL-4/mice (Fig. 2B). Produc-
in IL-4 /mice, but IgG1 was not induced by pristane,tion of IgG anti-chromatin antibodies was dramatically
consistent with its IL-4 dependence [28]. However, evenaccelerated by pristane treatment in IL-4 / mice (on-
though IgG2a was barely detectable in control IFN-set 2 to 3 months) vs. / controls (onset 6 months;
/ mice (Fig. 4, IFN- /, PBS), its production wasFig. 2B, top). The frequency of anti-chromatin was also
enhanced by pristane.higher in the IL-4/ versus/mice (P 0.05, Fisher
exact test; Table 2). Strikingly none of the pristane-
treated IFN- / mice produced IgG anti-chromatin DISCUSSION
antibodies (Fig. 2B and Table 2). Some wild-type and
Altered cytokine homeostasis is a feature common toIL-4 / mice showed low levels of spontaneous anti-
human and experimental lupus. It has been proposedchromatin activity (Fig. 2B, / PBS and IL-4 /
that SLE is mediated by TH2 cytokines such as IL-10PBS). This also was absent in IFN-/ mice, strongly
and IL-4 [18, 29]. The situation is less clear in murinesuggesting that autoimmunity to chromatin requires
IFN- as well as IL-6 [19]. There was a trend toward an lupus. IL-4 transgenic B6 mice develop spontaneous im-
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Fig. 2. Effect of pristane on autoantibody production in BALB/c mice. Sera were tested for autoantibodies (ELISA, 1:500 dilution) from baseline
(0) to 7.5 months after pristane or PBS treatment. (A) Levels of serum IgG anti-ssDNA antibodies at 7.5 months. (B) Levels of anti-chromatin
autoantibodies from 0 to 7.5 months. (C) IgG anti-nRNP/Sm activity. PBS-treated mice did not produce IgG anti-nRNP/Sm and are not shown;
/ pristane (N  18), / PBS (N  11); IFN- / pristane (N  22); IFN- / PBS (N  6); IL-4 / pristane (N  22); IL-4 / PBS
(N  6).
mune complex nephritis [30], but IL-4 transgenic NZW/ nephritis is incompletely understood. The present study
demonstrates that the TH1 cytokine IFN- is critical forC57Bl/6Yaa mice are protected [31]. TH1 cytokines have
been linked to both the production of nephritogenic au- the development of nephritis as well as autoantibodies
implicated in its pathogenesis in an inducible form of lupustoantibodies and renal disease in murine lupus nephritis
[20–22, 32]. Thus, the precise role of cytokines in lupus caused by exposure to the hydrocarbon oil pristane.
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Table 2. Frequency of autoantibodies in BALB/c mice
/ IL-4 / IFN- /
Pristane PBS Pristane PBS Pristane PBS
Number of mice 18 11 22 6 22 6

-chromatin 39% 0% 82%b 16% 0%a 0%

-dsDNA 39% 0% 41% 0% 9% 0%

-nRNP/Sm 78% 0% 82% 0% 22%a 0%

-Su 56% 0% 68% 0% 17%a 0%
Sera were obtained 7.5 months after treatment were analyzed for IgG anti-
chromatin (ELISA), anti-nRNP/Sm and anti-Su (ELISA and immunoprecipita-
tion), and anti-dsDNA (Crithidia assay).
a P  0.05 vs. pristane treated / and IL-4 / groups, Fisher exact test
b P  0.05 vs. pristane treated / group, Fisher exact test
Pristane-induced lupus nephritis is attenuated by
IFN- deficiency
Lupus nephritis induced by pristane resembles sponta-
neous lupus nephritis in MRL/lpr and NZB/W mice in its
IFN- dependence. Histological changes and proteinuria
were nearly absent in IFN-/mice following pristane
treatment, and immune complexes were markedly re-
duced. Moreover, glomerular immune deposits in IFN-
/mice were predominantly mesangial compared with
Fig. 3. Immunoprecipitation. Sera were analyzed by immunoprecipita-
the capillary deposits in / and IL-4 / mice (Table tion 7.5 months after treatment with pristane or PBS. Anti-nRNP/Sm
(proteins A, B/B, C, D, E/F and G) activity is apparent in lanes 1, 2, 3,1 and Fig. 1 E-H). Our previous studies on pristane-
6 and 8 and anti-Su in lanes 2, 3 and 6. Lanes 1, 2, and 3 show represen-induced nephritis confirmed that a mesangial immuno- tative samples from pristane-treated IL-4 / mice. Lanes 6 and 8
fluorescence pattern correlates with mesangial electron show 2 samples representative of the 5 IFN-/mice positive for anti-
nRNP/Sm showing that these autoantibodies were readily detectable bydense deposits, whereas capillary staining correlates with
immunoprecipitation. The increased intensity of non-specific bands in
subepithelial and subendothelial electron dense deposits pristane-treated IL-4 / is due to higher levels of IgG2a in this group.
All sera were tested and only representative samples are shown.[23]. Thus, IFN- has effects on the renal disease in
pristane-induced lupus akin to those in MRL/lpr [20, 22]
and NZB/W [32] mice. Whether this is due to reduced
production of nephritogenic antibodies or other effects
susceptibility to certain pathogens and the relative shift
such as altered clearance of immune complexes remains in immunoglobulin levels.
to be determined. There are several types of lupus ne- It is noteworthy that newly emerging evidence points
phritis, consistent with different pathogenic mechanisms. toward a critical role of Th1 cytokines in human lupus
It is clear that some forms of glomerulonephritis can nephritis [36] and there is some data to suggest that IFN-
develop in the absence of IFN- [33, 34], but further may be involved specifically in proliferative nephritis [37].
studies will be needed to determine if the pathogenesis Related interferons also may be involved in the pathogen-
of nephritis in pristane-treated mice differs in IFN- esis of lupus as evidenced by the finding of lupus-like fea-
deficient versus wild type mice. In view of the subepithel- tures in patients treated with interferon [38, 39].
ial localization of immune complexes in BALB/c mice Finally, although the relationship of pristane-induced lu-
and the suggested Th2-mediated pathogenesis of mem- pus to SLE remains uncertain, it may be relevant that hu-
branous nephropathy [35], it is tempting to speculate man hydrocarbon exposure has been reported to promote
that IFN- may promote capillary wall deposits with glomerulonephritis, but not other features of SLE [40].
proliferative nephritis, whereas IFN- deficiency might
Autoantibody production is IFN- dependenttend to favor the development of membranous lesions.
It is likely that the pathogenesis of the renal lesions in Glomerular autoantibody deposition is thought to play
both pristane-induced and spontaneous lupus is multifac- an important role in the pathogenesis of lupus nephritis
torial and the relative role of autoantibodies and local [1–3]. Anti-DNA, chromatin, nRNP/Sm, and Su auto-
factors are yet to be defined. There may also be a role antibody production was strongly regulated by IFN- in
for the potential secondary effects of IFN- or IL-4 defi- pristane-treated mice, suggesting that the development
of nephritis may be modulated through cytokine effectsciency on the disease pathogenesis such as the increased
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Fig. 4. Total immunoglobulin levels in IgG1 (A) and IgG2a
(B). Sera obtained 7.5 months after treatment were analyzed
for total IgG1and IgG2a (ELISA, 1:200,000 dilution). Levels
are in mg/mL.
on the production of pathogenic autoantibodies. Inter- responses whereas additional factors modulate the re-
sponse. IL-6, which influences the level of anti-nRNP/Smestingly, at least in the case of anti-nRNP/Sm, the pri-
but not the frequency, is a likely candidate [19].mary effect was on the probability of autoantibody for-
In summary, glomerulonephritis and the probabilitymation rather than on autoantibody levels (Fig. 2C).
of autoantibody formation were IFN- dependent inAlthough IL-4 transgenic mice produce antinuclear
pristane-induced lupus. In the case of anti-chromatinantibodies [41] and mice with chronic graft-versus-host
autoantibodies, the requirement for IFN- is more strin-disease develop a TH2 cytokine mediated lupus-like syn-
gent than for anti-nRNP/Sm or Su. Together with recentdrome [42], IL-4 exerted a mild protective effect on
findings in MRL/lpr and NZB/W mice, the present dataautoimmunity in pristane-induced lupus. IL-4 / mice
support the importance of TH1 cytokines in a subset ofshowed a trend toward higher autoantibody levels and
murine lupus. The development of anti-Sm and anti-more severe renal disease following pristane treatment
DNA antibodies by IFN- transgenic mice lends furtherthan wild type controls. The effect was modest on a
support to that idea [16]. The importance of IFN- inBALB/c background, but autoantibody levels were in-
human SLE remains controversial. However, the thera-creased40-fold in IL-4/B6 mice versus wild-type B6
peutic use of IFN-, especially in combination withcontrols (not shown). B6 mice are relatively resistant to
IFN-
-2b, can induce lupus autoantibodies as well asthe induction of nephritis by pristane, and nephritis could
disease [46], suggesting that IFN- promotes the devel-not be induced even in the absence of IL-4. Although
opment of lupus in a subset of humans as well as in mice.suggesting that IL-4 protects against pristane-induced
lupus, our data do not exclude the possibility that it
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